Tata Elxsi Launches ViTel, A Material Intelligence Solution for Med-Tech Powered by Viridium AI

On Wednesday, the Indian equity benchmarks traded higher during the afternoon session, with the benchmark Nifty 50 index rising 0.14 per cent to 23,947.70. IT and healthcare technology stocks remained in focus following product launches and AI-driven platform announcements. In this segment, Tata Elxsi share price remained in focus after the company launched ViTel, an AI-powered Material Intelligence solution for medical device manufacturers.

Tata Elxsi Launches ViTel

Tata Elxsi announced the launch of ViTel, a Material Intelligence platform co-developed with Viridium AI for medical device manufacturers.

The company formally introduced the solution at DeviceTalks Boston 2026 as part of its expansion in AI-powered MedTech engineering and regulatory support solutions.

According to the company, ViTel is designed to help medical device manufacturers improve sourcing and engineering decisions, protect margins and manage compliance requirements through AI-powered material intelligence.

Focus On Compliance And Supply Chain Visibility

Tata Elxsi stated that manufacturers currently face increasing complexity in global supply chains and regulatory frameworks, where material decisions impact product cost, continuity, resilience and market access.

The company said product-related information often remains fragmented across bills of materials (BOMs), supplier documents, ERP systems, PLM systems and expert teams, making regulatory and sourcing decisions time-consuming. ViTel aims to address these challenges by creating a reusable Material Intelligence layer across enterprise workflows.

The platform enables users to identify material and supplier dependencies, assess sourcing exposure and evaluate alternative materials and suppliers.

Powered By AI And Digital Twin Technology

The platform is powered by Viridium AI’s Knowledge Cloud, Chemical Digital Twin and science-constrained AI models.

According to the company, the system converts fragmented enterprise data into an integrated product-material knowledge graph connecting products, parts, materials, chemicals, suppliers and regulations.

Tata Elxsi added that its MedTech engineering and regulatory expertise has been integrated into the platform’s material risk and compliance assessment capabilities.

Management Commentary

Sreevatsa Sahasranaman, Senior Vice President and Head, Healthcare and Life Sciences, Tata Elxsi, said: “ViTel brings Material Intelligence directly into the product and compliance workflows that matter most, helping our customers make faster, more confident decisions across sourcing, engineering, quality, and regulatory readiness.”

Niraj Deo, Chief Executive Officer, Viridium AI, stated that the platform helps manufacturers understand the “material DNA” of products and convert product-material intelligence into a reusable enterprise asset.

Muthusamy Selvaraj, VP, Innovation and Partnerships, Healthcare and Life Sciences, Tata Elxsi, said the collaboration was developed through Tata Elxsi’s STEP UP co-innovation programme for deep-tech companies.

Stock Performance

Tata Elxsi Ltd shares were trading at Rs 4,334.75 during Wednesday’s afternoon session, marginally lower from the previous close of Rs 4,336.

The stock’s 52-week high and low stood at Rs 6,703.50 and Rs 3,977.25, respectively.

Shareholding Pattern

Foreign Institutional Investors (FIIs) increased stake in Tata Elxsi Ltd to 11.08 per cent from 8.57 per cent in the previous quarter. Domestic Institutional Investors (DIIs) reduced stake to 11.39 per cent from 12.29 per cent during the same period.

About The Company

Tata Elxsi Limited, incorporated in 1989 and headquartered in Bengaluru, provides product design and engineering services across transportation, healthcare, media and communications sectors.

The company operates globally through engineering centres and regional offices across North America, Europe, Asia and the Middle East.

What are your views on Tata Elxsi’s AI-powered ViTel platform and the future of AI-led healthcare engineering solutions? Share your thoughts in the comments below.
Disclaimer: This article is for informational purposes only and not investment advice.